Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer

Fig. 1

Patient no. 2 suffering from recurrent and metastatic AdCC of the right parotid gland. Imaging depicts moderate PSMA-ligand uptake in the recurrent parapharyngeal and intracranial tumour localizations: before (A, B and C) and after (D) therapy. A Coronal maximum intensity projection (before therapy SUVmax 6.5); B axial PET; C axial PET/CT reconstruction; D coronal maximum intensity projection (after therapy SUVmax 4.5)

Back to article page